AVCO believes the future of medicine will evolve toward cell-based therapeutics and diagnostics. Our “Avalon Cell” platform focuses on cell-based therapies and technologies with emphasis in the field of in vitro diagnostics, regenerative medicine and cancer immunotherapy.

AVCO leverages the clinical expertise of Daopei Medical Group and the strong technical background of our management team, to advance cell technologies globally. We focus on transformative and high-impact cell-based bio-tech opportunities in the U.S.A. and China, and fast track them to clinical development and commercialization worldwide.